Bioavailability and Bioequivalence

Bioavailability can be defined as the amount of drug available at the target site after systemic circulation and Bioequivalence is the similarity of two drugs which release the active ingredients at the same rate, amount, &quality. In such a process, the new drugs are tested for their stability studies. The new formulations have to undergo the analytical process to get approved by the FDA as an effective and safe dosage form. It has to compare new drug with the standard product as a reference.

  • In vitro & In vivo drug studies
  • Related Conference of Bioavailability
  • Cationic prodrugs as dual gene reagents
  • Chemically, therapeutically and physically bioequivalent.
  • Cationic prodrugs as dual gene reagents
  • HPLC to monitor β-lactam plasma
  • Accelerated stability studies
  • Chromatography types and techniques

Related Conference of Bioavailability and Bioequivalence

May 05-06, 2025

19th World Drug Delivery Summit

Vancouver, Canada
June 16-17, 2025

3rd Global Online Summit on Nanoscience and Nanotechnology

Zurich, Switzerland
June 23-24, 2025

38th World Congress on Pharmacology

Paris, France
August 18-19, 2025

40th World Congress on Pharmacology and Therapeutics

Valencia, Spain
September 22-23, 2025

Pharma Biotech Expo

Toronto, Canada
September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
November 20-21, 2025

21st Annual Congress on Pharmacology and Toxicology

Aix-en-Provence, France
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 27-28, 2025

13th International Conference on Clinical Trials

Amsterdam, Netherlands
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland

Bioavailability and Bioequivalence Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in